Many diabetes patients produce some insulin

June 22, 2017 by Elin Bäckström
insulin
High-resolution model of six insulin molecules assembled in a hexamer. Credit: Isaac Yonemoto/Wikipedia

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical journal Diabetes Care.

Type 1 diabetes, a chronic disease mainly debuting during childhood or adolescence, has previously been considered to result in full loss of the ' production. However, by the use of sophisticated insulin assays that have been introduced in recent years, this has now been shown to not be true in all cases.

In a study from Uppsala University more than one hundred type 1 at Uppsala University Hospital have been investigated. Almost half of the adult patients that have had type 1 diabetes for at least ten years still produced some insulin.

The study showed striking differences in the immune system between patients with full loss of their insulin production and patients that still produced some insulin. Patients with remaining insulin production had much higher blood levels of interleukin-35, a recently discovered anti inflammatory signal protein of the immune system. They also had many more immune cells that produce interleukin-35 and dampen immune attacks.

It is still not known if the patients had higher levels of interleukin-35 already at the onset of their disease, or if those levels had increased over the years, stopping immune attacks towards the as a result. A previous study by the same research group has shown that both patients newly diagnosed for type 1 diabetes and patients with long-standing disease on average have lower levels of interleukin-35 when compared to healthy individuals. The previous study also showed that diabetes development could be prevented, and that fully developed diabetes could be reversed, through interleukin-35 treatment in animal models with type 1 diabetes.

The results of the present study in Diabetes Care may increase the interest to develop interleukin-35 into a drug for the treatment of type 1 diabetes. The discovery that almost half of the patients with type 1 have some remaining also makes it attractive to let the patients test new treatments that can induce regeneration of their remaining insulin producing cells. Such a study has now been initiated at Uppsala University Hospital.

Explore further: Mislocalized calcium channel causes insulin secretion defect in diabetes

More information: Daniel Espes et al. Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide, Diabetes Care (2017). DOI: 10.2337/dc16-2121

Related Stories

Mislocalized calcium channel causes insulin secretion defect in diabetes

May 19, 2017
Researchers from Uppsala University have studied beta cells of type-2 diabetic donors, and find that a mislocalized calcium channel contributes to the failed insulin secretion associated with the disease.

Scientists study how some insulin-producing cells survive in type 1 diabetes

February 9, 2017
A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in ...

Pilot study shows stable insulin production in type 1 diabetes

February 16, 2017
A small pilot study in which researchers attempted to slow attacks mounted by the immune system on insulin-producing cells in type 1 diabetes has given promising results. The study by researchers at Linköping University ...

Researchers find biomarker that could help predict the onset of type 1 diabetes

March 28, 2017
A significant finding has been made by the 3U Diabetes Consortium, of Dublin City University, Maynooth University and the Royal College of Surgeons in Ireland (RCSI), which has the potential to contribute to the identification ...

Diabetes requiring insulin tied to increased stroke risk in A-fib

January 26, 2017
(HealthDay)—For patients with atrial fibrillation (AF), diabetes requiring insulin, but not diabetes without insulin treatment, is associated with an increased risk of stroke/systemic embolism, according to a study published ...

Protein packaging may cause the immune attacks of type 1 diabetes

November 21, 2016
Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Recommended for you

Pancreatic islets study may spur diabetes treatment advances

September 22, 2017
Investigators in the Vanderbilt Diabetes Research and Training Center (VDRTC) and collaborators at Stanford University have discovered new insights into the molecular mechanisms of cell proliferation in juvenile human pancreatic ...

Finding a natural defense against clogged arteries

September 20, 2017
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

September 14, 2017
A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes ...

Could swine flu be linked to type 1 diabetes?

September 14, 2017
(HealthDay)—Young people who've been infected with the H1N1 swine flu virus may be at increased risk for type 1 diabetes, a new study suggests.

Epigenetic 'fingerprint' identifies diabetes risk

September 14, 2017
Deakin researchers have identified an epigenetic marker that predicts risk of type 2 diabetes in women with gestational diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.